

About IAVI



Translating science
into global health impact

IAVI is a nonprofit organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.

Key program areas

IAVI brings together in-house researchers on infectious and neglected diseases, public and private partners, and local communities to develop and deliver vaccines and antibodies that are affordable and globally accessible. Here are the global health challenges we work on, some of the reasons we work on them, and what we're doing to help solve them.

▶ HIV

In 2022, 1.3 million people acquired HIV, primarily in low- and middle-income countries (LMICs). Treatment is still out of reach for many.

- Advance the next generation of vaccines to prevent HIV acquisition by pairing sophisticated science with community-rooted research.
- Develop injectable antibodies that can prevent HIV acquisition for as long as six months with one dose.
- Partner with Africa to end HIV through ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic), funded by a cooperative agreement with the U.S. Agency for International Development through the U.S. President's Emergency Plan for AIDS Relief.

▶ Tuberculosis (TB)

About one quarter of the world's population is infected with the bacterium that causes TB; 10.6 million people are estimated to have developed TB disease in 2021, resulting in approximately 1.6 million deaths.

- Conduct clinical trials of promising TB vaccine candidates in, and in partnership with, high-burden communities.

▶ Emerging Infectious Diseases

We need rapid, scalable vaccine technologies for diseases that pose public health and bio-terror threats.

- Apply our viral vector vaccine technology expertise to develop vaccines against Lassa, Marburg, and Sudan virus diseases, and COVID-19.

▶ Novel technologies and platforms

IAVI seeks to maximize the impact of novel technologies throughout our research portfolio so that innovations reach people in LMICs.

- Leverage our scientific, clinical, and access functions to improve access to innovative health solutions across disease areas.

▶ Product Development Center

IAVI's PDC bridges the "valley of death" in biomedical innovation development to help advance promising candidates from laboratory to clinic.

- Support for 53 biologics candidates to date, out of which 25 advanced to clinical trials.

IAVI fast facts

More than 25 years of breakthrough vaccine and antibody research

~350 employees

Staff in seven countries:
India, Kenya, Netherlands,
South Africa, Uganda, U.K., U.S.

Labs in La Jolla, California; Brooklyn, New York;
London, U.K.; and Faridabad, India

2022 revenue: \$128.1M

Revenue breakdown:
75.6% governments;
24.1% foundations and individuals;
0.3% other sources

501(c)(3) nonprofit organization

Pipeline 2023–2025

IAVI, in collaboration with partners in the public, private, and philanthropic sectors, develops vaccines and antibodies to address urgent, unmet global health challenges. Below is the pipeline as of July 2023. For the most updated list of current candidates, go to iavi.org.

IAVI products in development													
Candidate	2023				2024				2025				
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	
HIV vaccine candidates	eOD-GT8 60mer + Core-g28v2 60mer mRNA				Phase I (IAVI G002)								
	eOD-GT8 60mer mRNA				← Phase I (IAVI G003)								
	BG505 SOSIP gp140, adjuvanted (AS01B)				← Phase I (IAVI W001)								
	rVSVΔG-Env-HIV				Preclinical								
Passive immunization against HIV via bnAbs	bnAbs ePGT121v1, ePGDM1400v9, VRC01.23LS				Preclinical				Phase I				
	rVSVΔG-MARV-GP				Preclinical				Phase I (IAVI C104)				
Emerging infectious diseases vaccine candidates	rVSVΔG-LASV-GPC				Phase I (IAVI C102) / IIa (IAVI C105) / IIb (IAVI C111)								
	rVSVΔG-SUDV-GP				Preclinical → Phase I (IAVI C108, C109)								
	rVSVΔG-SARS-CoV-2				Preclinical				Phase I				
Tuberculosis (TB) vaccine candidates	MTBVAC* Phase Ib / IIa (A-050) →				Phase IIa (PLWHIV) / IIb								
	mRNA-encoded TB antigens				Preclinical								

* Trials in adults and adolescents. Biofabri is leading clinical development of the candidate in infants (currently in a Phase III trial).

IAVI-supported candidates													
Candidate	2023				2024				2025				
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	
HIV vaccine candidates	BG505 GT1.1 gp140, adjuvanted				Phase I (IAVI C101)								
	BG505 SOSIP gp140, adjuvanted (3M-052-AF + Alum)				Phase I (IAVI C107)								
	BG505 SOSIP gp140, adjuvanted (3M-052-AF + Alum)				Phase I (IAVI C110)								
	DNA-HIV-PT123, AIDSVAX®B/E; DNA-HIV-PT123, CN54gp140, MVA CMDR,CN54gp140; TAF/FTC; TDF/FTC				Phase III (PrePVacc)								
Passive immunization against HIV via bnAbs	bnAbs 3BNC117-LS-J and 10-1074-LS-J				Phase I / II (IAVI C100)								
TB vaccine candidates	H56/IC31® Phase II (A-055) →												
Mini-protein for COVID-19 prophylaxis	IPD-52520				Preclinical				Phase I (IAVI C106)				

IAVI gratefully acknowledges the generous support provided by the following major funders:



Biomedical Advanced Research and Development Authority (BARDA) | Foundation for the National Institutes of Health | National Institute of Allergy and Infectious Diseases | amfAR, The Foundation for AIDS Research | Broadway Cares/Equity Fights AIDS | The City of New York, Economic Development Corporation | Congressionally Directed Medical Research Program (DoD) | GSK | The Hearst Foundations | Keith Haring Foundation | Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the USA and Canada)

And many other generous individuals and partners around the world

As of January 2024